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Abstract
Background: The epidemiology of meningococcal disease in Mozambique and other African countries located outside the
‘‘meningitis belt’’ remains widely unknown. With the event of upcoming vaccines microbiological and epidemiological
information is urgently needed.
Methods: Prospective surveillance for invasive bacterial infections was conducted at the Manhic¸a District hospital (rural
Mozambique) among hospitalized children below 15 years of age. Available Neisseria meningitidis isolates were serogrouped
and characterized by Multilocus Sequence Typing (MLST). Antibiotic resistance was also determined.
Results: Between 1998 and 2008, sixty-three cases of confirmed meningococcal disease (36 meningitis, 26 sepsis and 1
conjunctivitis) were identified among hospitalized children. The average incidence rate of meningococcal disease was 11.6/
100,000 (8/100,000 for meningitis and 3.7/100,000 for meningococcemia, respectively). There was a significant rise on the number
of meningococcal disease cases in 2005–2006 that was sustained till the end of the surveillance period. Serogroup was determined
for 43 of the 63 meningococcal disease cases: 38 serogroup W-135, 3 serogroup A and 2 serogroup Y. ST-11 was the most
predominant sequence type and strongly associated with serogroup W-135. Two of the three serogroup A isolates were ST-1, and
both serogroup Y isolates were ST-175. N. meningitidis remained highly susceptible to all antibiotics used for treatment in the
country, although the presence of isolates presenting intermediate resistance to penicillin advocates for continued surveillance.
Conclusions: Our data show a high rate of meningococcal disease in Manhic¸a, Mozambique, mainly caused by serogroup
W-135 ST-11 strains, and advocates for the implementation of a vaccination strategy covering serogroup W-135
meningococci in the country.
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Introduction
Neisseria meningitidis is a major cause of meningitis and septicaemia
worldwide that often leaves survivors with severe sequelae [1].
Effective vaccination strategies have contributed to maintain the
rate of meningococcal disease (MD) low in industrialized countries
[2,3]. However, resource-poor countries continue to struggle with
this devastating disease. In the African meningitis belt, which
comprises all countries stretching across Africa from Ethiopia to
Senegal [4], incidence rates reach over 55/100,000 population [5]
and can surpass 1,000/100,000 during the large-scale epidemics
that are a unique characteristic of the belt [6]. Historically, disease
outbreaks in Africa have been caused by serogroup A [7], but a
Hajj-related serogroupW-135 strain emerged as an important cause
of disease in 2000 [8,9,10,11] and serogroup X meningocci have
also been recently associated with several outbreaks [12,13,14].
Despite concerns of a possible expansion of the meningitis belt
[15], data on MD from African countries outside this former area
are still scarce. Climate conditions and meteorological disasters
make Mozambique a country likely to suffer outbreaks of MD, and
various environmental modeling systems have forecasted epidem-
ics in northern and southern areas that appear yet to be
materialized [16,17,18]. The overall burden of disease reported
from Mozambique seems low, but the true nationwide incidence
remains unknown, as cases are often unreported despite the
existence of a national reporting system for communicable
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infectious diseases [19,20]. In Manhic¸a, a rural village in Southern
Mozambique, invasive bacterial infections are monitored by the
Centro de Investigac¸aˆo em Saude da Manhic¸a (CISM) among children
hospitalized at the Manhic¸a District Hospital (MDH) since 1998
[21,22,23]. Surveillance data revealed Streptococcus pneumoniae and
Haemophilus influenzae type b as the major cause of acute bacterial
meningitis in Manhic¸a among children #15 years of age, with N.
meningitidis being the third. However, whereas the prevalence
pneumococcal and Hib meningitis remained stable, the incidence
of meningococcal meningitis experienced a significant increase in
recent years [21,23]. Additionally, a study published by Zimba et.
al. suggested that the meningococcus is the first cause of meningitis
in the capital, Maputo [24].
This article presents data on the incidence, epidemiology,
molecular characteristics and antibiotic susceptibility of meningo-
coccal isolates obtained from patients admitted to the MDH over a
period of 11 years.
Materials and Methods
Study site and population
The study was conducted in the Manhic¸a district, located 80 km
north of Maputo and with an estimated population of 143,000
inhabitants, of which an estimated 26% are under 15 years of age
[25]. The climate is sub-tropical with a warm and rainy season
between November and April, and a cool and dry season during the
rest of the year. Malaria is endemic throughout the year, peaking
between December andMarch. The point-prevalence of HIV among
pregnant women in 2004 was estimated as 21%, but an increase from
18.4% in 2003 to 29% in April 2005 was observed [23,26].
A continuous Demographic Surveillance System (DSS) runs at
the CISM since 1996. Initially, the DSS covered a 100 Km2 area
and included 35,000 inhabitants. In August 2002 the area was
expanded to 400 Km2 and the population within the DSS
increased to 70,000. Currently, the area covers 500 Km2 and
includes 82,000 individuals. Information on births, deaths and
migration movements were collected and updated quarterly until
2000, and twice a year since. A unique permanent identification
number issued to all subjects living within the DSS area and
recorded in all hospital attendances at the MDH allows to link
morbidity and demographic data.
Case identification
Since 1997, a standardized clinical questionnaire is filled in upon
hospital admission for all patients, and outcome data recorded at
discharge [21,23]. All children with fever (axillary temperature
$37.5) or with a history of fever are tested for malaria parasites in
blood. Blood cultures were performed routinely since 1998 to all
admitted children ,2 years of age, for older children with axillary
temperature .39uC, and for those presenting symptoms compatible
with sepsis or neurological impairment. Prior to 2006, lumbar
punctures (LP) were performed to all children presenting neurological
signs compatible with meningitis at the clinician’s criterion, and
cerebro-spinal fluid (CSF) samples were processed only for bacterial
isolation. In January 2006, and enhanced meningitis surveillance was
established and criteria for the collection of CSF on cases of suspected
meningitis were standardized [21]. Additionally, LP was since
performed to all neonates (,28 days of age) admitted to hospital
with fever or suspected neonatal sepsis. CSF samples were processed
following a standardized protocol as described in Roca et. al. [21].
Ethics
The implementation of the enhanced meningitis surveillance
was approved by the Mozambican National Bioethics Committee
and the Institutional Review Board of the Hospital Clinic of
Barcelona. The ethics committee did not require informed consent
from patients as the surveillance involved improvements in clinical
criteria and management of cases with suspected meningitis that
were incorporated into the hospital’s standard operational
procedures.
Case definition
Laboratory-confirmed meningococcal disease was defined as
the presence of N. meningitidis in a normally sterile body fluid.
Meningococcemia was defined as isolation of N. meningitidis from
blood and not from CSF. Meningitis was defined as (i) isolation of
the bacterium in CSF regardless of its presence in blood; or (ii)
positive latex agglutination for N. meningitidis antigens in a
purulent CSF. Purulent CSF was determined by a turbid
appearance, a leukocyte count of $1006106/L or a leukocyte
count of $10–996106/L in combination with either a glucose
level of ,40 mg/dL or the presence of protein as determined by
the Pandy test [27]. Meningococcal conjunctivitis was defined as
the isolation of N. meningitidis from a purulent ophthalmic
exhudate.
Treatment guidelines
Mozambique national recommendations for the treatment of
suspected meningitis include the administration of intravenous
chloramphenicol (100 mg/Kg/day) or combinations with intra-
venous penicillin G (2 500.000 ui/Kg/day) plus gentamicin (daily
5–7.5 mg/kg). Infants under 2 months are treated with ampicillin
(200 mg/Kg/day) and gentamicin (5 mg/Kg/day). Treatment is
reassessed once bacteriological results and antibiotic susceptibility
are known. When available, ceftriaxone (100 mg/Kg/day) is used
in all confirmed meningitis cases until the antibiotic susceptibility
pattern is obtained. Direct contacts of MD patients are
administered rifampicin for prophylaxis (20 mg/kg/day for 2
days) [21].
N. meningitidis identification
Gram-negative diplococci, oxidase, catalase positive and
capable of fermenting glucose were identified as N. meningitidis.
Isolates were stored at 280uC in a vial containing skim milk.
Additional identification tests (e.g. latex agglutination) were
performed for the purpose of this study upon culture when in
doubt.
N. meningitidis culture and DNA extraction
Isolates were retrieved from the freezer and cultured in
Columbia agar base with horse blood. Plates were incubated at
37uC in an atmosphere of 5% CO2. Growth was checked after
12 h, and a single colony was re-plated following the same
procedure. DNA extractions were performed using the Qiagen
DNA Mini Kit (Qiagen).
Serogroup determination
Since 2006, latex agglutination test for serogroups A, B, C
and W-135/Y (PastorexH test, BioRad) were routinely per-
formed in all CSF samples rendering a positive gram stain or
cell count. A previously published Polymerase Chain Reaction
(PCR) assay was used to ascertain the serogroup in all viable
isolates [28].
MultiLocus Sequence Typing (MLST)
Viable isolates were characterized by MLST as described by
Maiden et al. [29]. The internal fragments of seven housekeeping
Meningococcal Disease in Manhic¸a, Mozambique
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genes were amplified by PCR and the forward and reverse strands
were sequenced at the Macrogen Inc. facility in Seoul, Korea.
Allele designations were determined by querying the Neisseria
MLST database (www.pubmlst.org/neisseria). New MLST pro-
files were sent to the database curator at the University of Oxford
for designation.
porA and fetA variable region typing
Following the guidelines of the European Monitoring Group for
Meningococci (EMGM), the variable regions of the antigens porA
and fetA were determined as previously described [30] and
designated by querying the databases on www.neisseria.org/nm/
typing.
Antibiotic susceptibility testing
Antibiotic susceptibility and Minimum Inhibitory Concentra-
tions (MICs) for chloramphenicol, penicillin G, gentamicin,
rifampicin and trimethoprim-sulfamethoxazole (cotrimoxazole)
were determined by EtestH (AB Biodisk, Solna, Sweden) following
the manufacturer’s recommendations, and results were interpreted
according to NCCLS standards.
Data Management and Analysis
Questionnaire data are routinely double-entered and stored in a
proprietary database following the standard procedures at CISM.
Incidence rates ratios (IRR) and 95% CI rates were calculated
among children living within the DSS area at the time of the
disease onset using the number of laboratory-confirmed cases of
meningococcal disease, meningitis and meningococcemia as
defined previously, and on positive blood cultures regardless of
evidence of N. meningitidis in CSF. Time at risk was calculated as
the number of person years at risk since the beginning of the time
at risk until the end of follow-up, 15 years of age, migration or
death, whatever occurs first. All analyses were performed using
Stata/SE 11 for Windows.
Results
A total of 42,374 children under15 years of age were admitted
to the Manhic¸a district hospital between 1st of January 1998 and
31st of December 2008 (mean annual admission 3,856), of which
2,587 (6.1%) were hospitalized with suspected meningitis. Sixty-
three cases (2.4%) of MD were identified among these patients.
The median age of the cases was 30 months and 54% were male.
By age groups, 30.2% of the cases occurred among children ,1
year, 34.9% were aged 1–,4 year, 23.8% 4–,10 years and those
aged 10–15 years represented 11.1% of patients.
Thirty-six cases presented meningococcal meningitis (57%), six
of which were negative by culture but could be detected by latex
agglutination test. Seventeen (27%) of these patients had
concurrent meningococcemia. Twenty-six patients (41%) present-
ed meningococcemia alone. One isolate was obtained from the
ophthalmic exudate of a purulent conjunctivitis case (Figure 1).
Incidence rates
Minimum community-based incidence rates for meningococcal
disease among children #15 years of age living within the study
area were calculated (n= 35). Table 1a shows the overall incidence
rates for meningococcal disease and those based on the number of
positive blood cultures, as well as the rates for meningitis and
meningococcemia in different age groups. The overall incidence
rate of meningococcal disease for the period 1st January-1998 –
31st December 2008 was 11.6/100.000 child-year at risk. The
incidence of meningococcal meningitis doubled that of meningo-
coccemia (8/100.000 vs. 3.7/100.000). The highest incidence rates
on all presentations of meningococcal disease, were seen among
children ,4 years of age, with rates halving among those aged 4–
,10 years, and rising again among teenagers.
Disease rates fluctuated over the years (table 1b), but a
significant increase on the incidence of MD occurred in 2005
and was sustained until the end of the study period.
Figure 1. Total number of N. meningitidis isolated from blood, CSF and other sterile fluids vs. total number of admissions to the
MDH for the period 1998–2008.
doi:10.1371/journal.pone.0019717.g001
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Clinical data on meningococcal disease
Among the 36 meningitis cases, the average time from disease
onset to hospitalization, measured as the number of days from
the referred onset of fever, was 3 days, and the mean
hospitalization time was 8 days. A total of 27 (75%) meningitis
patients had fever at the time of hospitalization (mean
temperature 38uC). At least one episode of convulsions occurred
in 10 (28%) of these patients. Neck stiffness was present in 16
out of 28 (57%), and a bulging fontanellae was observed in 3
children out of the 8 for whom this criteria was applied (age
,1,5 year) Anorexia and vomiting were present in 13 (36%) and
10 (28%) meningitis patients respectively. Two patients (8%),
aged 2 and 10 years respectively, died of meningitis within 24 h
of presenting fever, and one was transferred to the Central
hospital in the capital, Maputo.
For the 26 meningococcemia cases, the average time from the
start of fever to hospital attendance was 2 days and the mean
hospitalization time was 5 days. A total of 21 (78%) of these
patients presented fever at the time of hospitalization (mean
temperature 38.2uC). None of the patients diagnosed with
meningococcemia presented neck stiffness; however, three patients
experienced fits (12%). Vomiting and anorexia was seen in 19
(73%) and 5 (19%) of these patients respectively. One 5 years old
child (4%) with meningococcemia died four days after disease
onset and another one absconded hospital and final outcome is not
available (Table 2).
Data on malaria parasitemia was available for 31(86%)
meningitis and 23 (88%) of meningococcemia cases. A total of 5
meningitis (16% of 31 cases with data available) and 9
meningococcemia patients (39% of 23 with data available) showed
evidence of Plasmodium falciparum parasites in their blood.
The conjunctivitis case was 19 days old newborn presenting
with dehydration and fever for one day before hospitalization. The
patient had a negative blood culture and was also negative for
malaria.
Isolate collection
A total of 63 cases of laboratory-confirmed MD were admitted
at the MDH over the surveillance period. Among those, 48 isolates
(26 from blood, 21 from CSF and one from a purulent ophthalmic
exudate) obtained from 37 patients were available for genetic
characterization and antibiotic susceptibility testing. Isolates
obtained from blood and CSF from the same patient were
available for 11 cases.
Meningococcal serogroups
Serogroup by latex was determined for 21 of the 36 cases (55%)
of laboratory-confirmed meningitis. Serogroup was determined by
PCR [31] for all 37 cases of meningococcal disease from whom
isolates were available. In all cases for which two isolates were
available, serogroup results on blood and CSF were concordant.
Latex agglutination and PCR results were concordant in all but
one sample, which was reported non groupable on agglutination,
but positive for W-135 by PCR. Latex agglutination results were
available for 6 additional cases from whom the original isolate was
no longer available for PCR confirmation.
For the total 43 cases of meningococcal disease for which the
serogroup of the causative strain was determined (21 by latex and
PCR, 16 by PCR and 6 by latex alone), 38 (88%) were caused by
serogroupW-135, 3 (7%) were serogroup A, and the remaining 2
(5%), serogroup Y. Serogroup W-135 isolates were first detected in
1998 and continued to be seen throughout the years with a
substantial upsurge since 2005. Serogroup A isolates were seen in
1999, 2003 and 2006. Serogroup Y isolates were detected in 1999
and 2007 (Figure 1).
Genetic characterization
From the 48 N. meningitidis isolates characterized by MLST porA
and fetA, 26 (54%) were isolated from blood samples, 21 (44%)
were obtained from CSF, and 1 (2%) came from an eye exudate.
Isolates came from a total of 37 cases of disease.
Five different STs belonging to 3 different clonal complexes
were identified among the isolates. ST-11 complex was the cause
of disease in 31 patients (84% of cases for which MLST was
performed). Two novel STs were detected and assigned as ST-
7464 and ST-7465. ST-7464 differs in two loci from ST-11 and
belongs to this clonal complex. The ST-7465 isolate obtained from
the conjunctivitis patient does not belong to any of the known
Table 1. Minimum Incidence rates of meningococcal disease according to age groups, disease presentation and year of
surveillance. Only cases from children residents from the DSS are included.
Overall rate ,1 years 1–,5 years 5–,15 years
Number
of
patients Rates (95% CI)
Number
of
patients Rates (95% CI)
Number
of
patients Rates (95% CI)
Number
of
patients
Rates (95%
CI)
Meningococcal disease 35 11.6 (8.4–16.2) 7 26.9 (12.8–56.4) 14 15.1 (9–25.5) 14 7.7 (4.6–13)
Meningitis 24 8 (5.4–11.9) 2 7.7 (1.9–30.7) 11 11.9 (3.3–10.9) 11 6 (3.3–10.9)
Bacteraemia 11 3.7 (2–6.6) 5 19.2 (8–46.1) 3 3.2 (1–10) 3 1.6 (0.5–5.1)
Positive blood culture 25 8.3 (5.6–12.3) 6 23 (10.4–51.3) 10 10.8 (5.8–20.1) 9 4.9 (2.6–9.5)
Overall Meningitis Bacteraemia Blood culture
Time period
Number
of
patients Rates (95% CI)
Number
of
patients Rates (95% CI)
Number
of
patients Rates (95% CI)
Number
of
patients
Rates (95%
CI)
1998–2001 4 6.5 (2.4–17.3) 1 1.6 (0.2–11.5)_ 3 4.9 (1.6–15.1) 4 6.5 (2.4–17.3)
2002–2004 6 6.9 (3.1–15.3) 4 4.6 (1.7–12.2) 2 2.3 (0.6–9.2) 5 5.7 (2.4–13.8)
2005–2008 25 16.5 (11.1–24.4) 19 12.5 (8–19.6) 6 4 (1.8–8.8) 16 10.5 (6.5–17.2)
doi:10.1371/journal.pone.0019717.t001
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clonal complexes to date, but its genetic profile shares 6 of the 7
loci with Neisseria gonorrhoeae isolates listed on the pubmlst database.
The seventh allele, fumC3, is in common with ST-11 N. meningitidis.
This isolate, along with all ST-11 complex isolates belonged to
serogroup W135. ST-1 and ST-175 were each identified in two
patients and had serogroup A and serogroup Y capsule
respectively.
A total of six different porA types were found among the isolates,
all but one belonging to VR1 family 5 and VR2 family 2. The ST-
7465 isolate obtained from the conjunctivitis sample had a porA
type unrelated to those found among the other isolates and found
to be common to N. gonorrhoeae.
Four different fetA variants were identified among the strains,
three of which belonged to family five, and one to family one, with
the latter being exclusively associated to ST-11. It was not possible
to determine the porA and fetA variants for the ST-7464 isolate
(Table 3).
Antibiotic susceptibility
One patient diagnosed with meningococcemia in 1998 har-
boured a strain that was resistant to chloramphenicol, rifampicin,
penicillin and trimethoprim-sulfamethoxazole. All other isolates
were susceptible to chloramphenicol, rifampicin and gentamicin.
One patient presented a penicillin resistant strain, and there was one
case caused by a strain with intermediate resistance to penicillin.
Twenty-on patients had isolates with intermediate resistance to
trimethoprim-sulfamethoxazole and 2 patients harboured strains
that were fully resistant to this drug. When blood and CSF isolates
from the same patient were available, results were concordant for all
antibiotics in all but one of the 11 patients, who appeared to have an
isolate resistant to trimethoprim-sulfamethoxazole in CSF but
susceptible in blood (Table 4).
Discussion
These data represent the first published study specifically on the
characterization and incidence of meningococcal disease in
Mozambique. The minimum incidence rates reported here are
unusually high for an area situated outside the meningitis belt but
yet below the high rates reported from the belt [5,32]. However,
our data underestimate the real community burden, as we
presume that many additional cases never reached the hospital.
Prior to 2006, LPs were rarely performed to children with no
obvious signs of meningitis [27]. The standardisation of clinical
criteria to identify suspected cases of meningitis in 2006 will have
resulted in more cases being identified and therefore incidence
rates calculated from 2006 onwards are expected to be more
accurate. However, blood culture procedures have remained
unchanged over the study period and incidence rates estimated
from the number of positive bloods are comparable from year to
year, which allows to asses an increase in the incidence of MD
since 2005.
The highest incidence of meningococcal disease in the Manhic¸a
district was seen among infants ,1 year. Incidence rates among
infants in Manhic¸a were seen to be similar to those reported from
South Africa [33]. Serogroup W-135 meningococci have been
associated with high rates of disease among the youngest, whereas
serogroup A appears to affect more frequently older children and
adults [10,33]. The high prevalence of serogroup W-135 over
serogroup A in our population might explain why the median age
of MD cases in Manhic¸a is low.
The meningococcal strain responsible for most cases was the
same that caused the Hajj-related global outbreak of MD in 2000
[8] and to which various epidemics in the meningitis belt were
attributed to [10,34,35]. This strain was also associated to a rise in
endemic disease and a high mortality in neighbouring South
Africa [33]. The upsurge of this strain among MD patients during
2005 and 2006 was similar to that described in South Africa
[33,36], and might be explained by continuous migration
movements young males from Manhic¸a to the neighbouring
country in search of work.
The overall mortality rate for the 11-year period due to MD in
Manhic¸a was low (5%, 3 out the 61 cases with known outcome)
compared to the average 8% mortality seen among other African
countries [37]. This also contrasts with the high case-fatality rates
of 22% reported in South Africa, associated with ST-11 W-135
meningococcemia [33]. It is likely that some of the more severe
cases of MD never reached hospital as it has been reported that
54% of deaths of children #15 years in the Manhic¸a area occur
outside health facilities [38].
Table 2. Clinical symptoms associated with meningococcal meningitis and bacteraemia among patients treated at the MDH
between 1998–2008.
Meningococcemia cases (%) (n =26) Meningitis cases (%) (n=36)
Disease onset 2 days 3 days
Hospitalization time 5 days 8 days
Fever at arrival 21(78) 27(75)
Mean temperature at arrival 38.2uC 38uC
Convulsions 3(12) 10 (28)
Neck stiffness 0 16 (44)
Bulging fontanelle (children ,1 year) 0 **3 (38)
Anorexia 5(19) 13(36)
Vomiting 19(73) 10(28)
Malaria parasites* 9(39)* 5 (16)
Death 1(4) 2(8)
Unknown outcome 1(4) 1(3)
*n = 23 for meningococcemia and n = 31 for meningitis).
**out of 8 children ,1 year of age.
doi:10.1371/journal.pone.0019717.t002
Meningococcal Disease in Manhic¸a, Mozambique
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e19717
Since the Hajj-related outbreak of 2000, disease caused by W-135
meningococci has became endemic in many sub-Saharan African
countries and caused sporadic epidemics. Furthermore, meningococ-
cal carriage studies in sub-Saharan Africa have detected a high
prevalence of the W-135:P1.5,2:ST-11 meningococcal strain among
asymptomatic carriers [39,40] which has led to debates on the
necessity of including W-135 as part of any vaccination strategy being
developed for this region of the world. Our data fully support the need
for such vaccine, specially among African countries outside the
meningitis belt, where the epidemiology of the disease and disease-
causing strains differs greatly from that observed in the meningitis belt.
Serogroup A was the cause of disease in 3 (7%) of the cases, and
the two viable isolates were characterized as A:P1.5,2-10:F5-
1:ST1. Disease caused by this serogroup is associated with older
infants and adolescents [10,33], and although it is likely that our
study missed some cases occurred among those over the age of 15,
it is unlikely that data would significantly change our conclusions
regarding the prevalence of this serogroup in the south of the
country. However, data in the north of Mozambique should be
needed to ascertain the burden of serogroup A.
The fact that the two cases of meningococcal disease caused by
Y:P1.5-1, 2-2: F5-8: ST-175 are separated in time and location
could suggest that meningococcal disease caused by this strain
would be an sporadic event rather than a circulating endemic
strain. However, the identification of one case caused by the newly
detected W-135:ST-7564, which is identical to ST-11 except for
the two alleles that shares with ST-175, abcZ and aroE, evidences
recombination between ST-11 and ST-175 meningococci and
hence long-term contact between these two STs. Asymptomatic
carriage of ST-175 was seen in the Gambia [39], Niger [41]and
Burkina-Faso [40] and is not unreasonable to suspect that this
strain also circulates among asymptomatic carriers in Manhic¸a.
Neonatal conjunctivitis is a rare and under-investigated
presentation of disease caused by Neisseria pathogenic species.
The discovery of the ST-7465 strain, a w-135 capsulated
meningococcus presenting a genetic profile that suggests it might
be the result of recombination between N. meningitidis and N.
gonorrhoeae proves that this phenomenon can occur, but is rare as
they do not often converge in the same environment. It is likely the
newborn acquired the recombinant strain on the birth canal [42].
N. meningitidis isolated from cases in theManhic¸a district remained
generally susceptible to those antibiotics commonly administered for
the treatment of meningitis in Mozambique. However, meningo-
cocci with resistance to penicillin were detected among our isolates.
Such isolates were also detected in South Africa, but are rarely
reported from anywhere else in the continent [43]. As our work
reveals, this could be due to a lack of data and their presence should
not be ruled out in other African countries. A total 52.1% of the
isolates tested presented intermediate or full resistance to cotrimox-
azole. The widely-extended use of sulphonamides (Sulphadoxine-
pyrimethamine) in Mozambique as treatment for uncomplicated
malaria during most of the study period or as intermittent
preventive treatment among pregnant women, and the use of
cotrimoxazole as prophylaxis against Pneumocystis jirovecii pneumonia
in HIV positive patients have resulted in the selection of resistant
bacterial strains. This phenomenon has also been observed among
pneumococci and non-typeable Salmonella isolates in the area [27].
Data generated from this long surveillance provide very strong
evidence for the need to evaluate the introduction of W-135
meningococcal vaccines in countries outside the meningitis belt
such as Mozambique. However, data on the epidemiology of MD
from Northern Mozambique, where population and migration
movements are different from those in the South, and data on
disease on a wider age-range are necessary to support our findings.
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Table 3. Strains of N. meningitidis isolated by year from patients of meningococcal disease attended at the MDH from 1998–2008.
Year
Strain type 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Total
ST-1 complex
A:P1.5,2-10:F5-1:ST1 1 1 2
ST-11 complex
W135:P1.5,2:F1-1:ST11 1 1 9 10 7 11 39
W135:P1.5,2-2:F1-1:ST11 1 1 2
W135:P1.5,2-38:F1-1:ST11 1 1
W-135: P1.ND,ND: F-ND: ST-7464 1 1
ST-175 complex
Y:P1.5-1, 2-2: F5-8: ST-175 1 1 2
Unassigned
W-135:P1.18-10,43:F5-24: ST-7465 1 1
doi:10.1371/journal.pone.0019717.t003
Table 4. Susceptibility testing results for 37 invasive
meningococcal disease patients.
R$ I S#
Chloramphenicol 1* 36
Rifampicin 1* 36
Penicillin 2* 1 34
Trimethoprim-Sulfamethoxazole 2* 21 14
Gentamicin 37
*One isolate was resistant to all these drugs.
doi:10.1371/journal.pone.0019717.t004
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